Bullous pemphigoid (BP) is the most common form of autoimmune bullous dermatosis.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Documentation for bullous pemphigoid is limited due to its relatively rare occurrence and the complexity of its clinical features, which can overlap with other autoimmune conditions. As BP affects fewer than 5 in 10,000 people, systematic studies have been scarce. This rarity can hinder the development of comprehensive clinical guidelines and understanding of the disease's underlying mechanisms.
To navigate your care for bullous pemphigoid, consider seeking a dermatologist who specializes in autoimmune skin disorders. They can provide targeted treatment options and monitor your condition effectively. Additionally, explore opportunities to participate in clinical trials, which may offer access to cutting-edge therapies. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide further insights and support. While no specific patient organizations are identified, connecting with dermatology clinics may help you find community support.
There are currently 12 active clinical trials investigating various treatment options for bullous pemphigoid. Notably, dupilumab is an FDA-approved treatment, while drugs such as bertilimumab, nomacopan, and rituximab are designated for development. These therapies aim to address the autoimmune response associated with BP. For more information about ongoing trials, you can visit ClinicalTrials.gov and search for bullous pemphigoid: https://clinicaltrials.gov/search?cond=bullous%20pemphigoid.
Actionable guidance for navigating care for bullous pemphigoid
To navigate your care for bullous pemphigoid, consider seeking a dermatologist who specializes in autoimmune skin disorders. They can provide targeted treatment options and monitor your condition effectively. Additionally, explore opportunities to participate in clinical trials, which may offer access to cutting-edge therapies. Resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide further insights and support. While no specific patient organizations are identified, connecting with dermatology clinics may help you find community support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 6 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning bullous pemphigoid
Updated Feb 15, 2026
Recent research highlights the need for optimized local treatment strategies in pemphigus and pemphigoid, addressing current evidence and unmet needs in patient care. This study emphasizes the importance of tailored approaches to improve outcomes for affected individuals.